Published in final edited form as:

Bioorg Med Chem Lett. 2011 May 1; 21(9): 2601–2605. doi:10.1016/j.bmcl.2011.01.134.

Discovery of histone deacetylase 8 selective inhibitors

Weiping Tang^{a,b,*}, Tuoping Luo^a, Edward F. Greenberg^a, James E. Bradner^a, and Stuart L. Schreiber^{a,*}

^a Howard Hughes Medical Institute, Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA

Abstract

We have developed an efficient method for synthesizing candidate histone deacetylase (HDAC) inhibitors in 96-well plates, which are used directly in high-throughput screening. We selected building blocks having hydrazide, aldehyde and hydroxamic acid functionalities. The hydrazides were coupled with different aldehydes in DMSO. The resulting products have the previously identified ‘cap/linker/biasing element’ structure known to favor inhibition of HDACs. These compounds were assayed without further purification. HDAC8-selective inhibitors were discovered from this novel collection of compounds.

Keywords

HDAC; HDAC8; Macrocycle; Inhibitor; Hydroxamic acid

Eukaryotes package their genome into nucleosomes, where DNA is tightly wrapped around an octamer of core histones (two each of the H2A, H2B, H3 and H4).¹ Modifications and the positioning of histones organize the genome into either open or condensed chromatin and by creating docking sites, and thus regulate the accessibility of DNA for diverse cellular processes, from transcription, replication, to DNA repair.² Encoded in the human genome are 11 zinc-dependent human histone deacetylases (HDACs) that catalyze the hydrolysis of e-acetyl group of acetylated lysine on histone proteins.^{3,4} The acetylation status of histone and non-histone proteins plays an important role in the modulation of transcription, microtubule structure and function, the cell cycle, among others.⁵ Small-molecule inhibitors of HDACs such as trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), trapoxin B, tubacin and histacin (Figure 1), played an important role in both the discovery of HDACs and in the elucidation of their functions.^{3,6-9} HDAC inhibitors that have undergone or are undergoing clinical investigation have little selectivity towards individual HDACs.^{8,10} Selectively inhibiting a single HDAC or a subclass of HDACs is currently a major focus of HDAC inhibitor design. Selective HDAC inhibitors, for example tubacin, not only can elucidate the function of individual HDAC but also provide candidates with less side effects for the treatment of cancer or other diseases.¹¹ However, only limited progress towards the discovery of these agents has been made to date.^{6-8,12,13}

© 2011 Elsevier Ltd. All rights reserved.

*Corresponding authors. Tel.: +1-608-890-1846; fax: +1-608-262-5345 (W.T.); wtang@pharmacy.wisc.edu Tel.: +1-617-714-7080; fax: +1-617-714-8969 (S.L.S.); stuart_schreiber@harvard.edu; .

^bCurrent address: School of Pharmacy, University of Wisconsin, Madison, WI 53705, USA

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Structural studies of HDACs and related proteins revealed that the active site and the channel that accommodates the aliphatic chain of HDAC inhibitors such as TSA are highly conserved.¹⁴ The structural diversity of the HDACs lies in a region peripheral to the catalytic site.¹⁵ This sequence diversity in the periphery suggests that selective inhibitors may be identified from collections of compounds having varied groups that can interact with the residues in this region. In addition, HDACs exist in numerous protein complexes and the enzymatic activities of HDACs are often dependent on or regulated by these complexes. Small molecules with diverse structures that can interact with the peripheral regions of HDACs may provide selectivity for certain protein complexes.

The coupling of compounds having diverse structural features with compounds that can interact with the conserved active site, such as biasing reagents for HDACs, has provided one strategy for the discovery of isozyme-selective inhibitors.^{6,7} Ideally, the coupling chemistry should be compatible with diverse functional groups and efficient – with minimal or ideally no purification required – and suitable for miniaturized high-throughput synthesis and screening.

A two-step process for the conversion of primary alcohols to HDAC inhibitors was envisioned as shown in Figure 2.¹⁶ Primary alcohol **1** was first oxidized to aldehyde **2** using a polymer-supported oxidation reagent.^{17,18} Excess reagents can be used to drive the reactions to completion and can be removed by simple filtration. Condensation of the resulting aldehyde **2** with HDAC-biasing compound **3** that possess both hydrazide and hydroxamic groups yields hydrazone **4**. The hydroxamic acid group with a suitable linker element is known to bias the resulting compounds towards the inhibitions of HDACs.⁸ For example, trichostatin A has a hydroxamic acid as its metal-chelating group.

We selected 12-membered macrocyclic lactams functionalized with zinc ion-binding elements as core structural features of compounds comprising an initial pilot library. A number of naturally occurring HDAC inhibitors are 12-membered cyclic tetrapeptides, including trapoxin, chlamydocin, HC toxin, apicidin, Cyl-1, Cyl-2 and FK228.⁸ Epoxyketones, ketones, hydroxyketones and thiols function as metal-chelating groups in these macrocyclic HDAC inhibitors. Structurally diverse synthetic analogues of the above natural products have been identified as HDAC inhibitors including a hydroxamic acid-containing cyclic peptide (CHAP).¹⁹ These cyclic tetrapeptides are among the most potent HDAC inhibitors. However, syntheses of these inhibitors are generally complex, requiring more than 20 steps.^{3,20} Macrocyclic lactam **11** shown in Figure 3, on the other hand, can be prepared in a few steps according to previously established methods.²¹ The ring closing metathesis (RCM) using Grubbs' first generation catalyst²² gave *trans* olefin **10** predominantly. Alcohol **11** can then be oxidized efficiently to aldehyde **A6** using solid support reagents.¹⁷ Macrocyclic lactams **A1** – **A11** (Figure 5) were synthesized according to the procedure shown in Figure 3. The *E/Z* selectivity for the RCM reaction varies from 5:1 to over 10:1.²³

Bifunctional reagents having hydroxamic acid and other chelating groups and linkers with different length and rigidity were synthesized as shown in Figure 4.

Reactions of hydrazine with dimethyl diester **12** (in excess) yielded mixtures of mono- and dihydrazides. Pure monohydrazides were obtained after silica gel filtration. Treatment of the resulting monohydrazides with hydroxylamine under basic conditions afforded simple bifunctional reagents **B1** – **B3**. The mono hydrazides can also be prepared from corresponding monoacid **13** via activation followed by hydrazinolysis. Bifunctional reagents **B4** and **B5** with a benzene ring within the linker were prepared in two steps. Nonsymmetrical linkers were used in bifunctional reagents **B6** – **B13** via a four-step

protocol from corresponding hydroxybenzaldehyde **14** or its substituted counterparts. Bifunctional reagents **B14** – **B16** containing orthohydroxyanilides and **B17** – **B18** containing carboxylic acids as the biasing reagents were also prepared following similar procedures.

A library of small molecule inhibitors of HDACs was synthesized from 18 bifunctional biasing reagents **B1** – **B18** (Figure 4) and 15 aldehydes **A1** – **A15** (Figure 5) in 96-well plates yielding milligram quantities of each final product. LC-MS showed that acylhydrazones are formed as the exclusive products with over 90% purity. The DMSO solution of the reaction products in 96-well plate was directly used for subsequent screening.

Using protocols established previously,^{7,10,24,25} the resulting compounds were tested in biochemical assays against HDAC2, HDAC3, and HDAC8 (Table 1). Several HDAC8-selective inhibitors **A8B4**, **A12B4**, and **A14B4** (Figure 6) were discovered. Reagent **B4** is biased towards HDAC8 as judged by the observation that several products derived from it are selective for HDAC8 (Table 1).¹³

Biasing reagents **B1** – **B18** were also coupled with hundreds of commercially available aldehydes to generate thousands of HDAC inhibitors that showed diverse biological activities.^{10,24,26}

In summary, we developed an efficient strategy for rapid assembling and in-situ screening of HDAC inhibitors. Biasing reagents **B1** – **B18** were prepared in a few steps in solution and then coupled with macrocyclic aldehydes, which were derived from corresponding primary alcohols using solid supported oxidation reagents. Simple filtration was used to remove the excess oxidation reagents. The coupling step is efficient and does not require purification since its only byproduct is water. The resulting solution from the coupling reaction can be directly used for biological assays since DMSO was used as the solvent. Selective HDAC8 inhibitors, such as **A8B4**, were identified.

Small-molecule probe or tool compounds can be used to illuminate the functions of proteins and to identify new therapeutic targets.²⁷ The method described here allows efficient coupling of structurally diverse compounds and reagents having structural features that facilitate the inhibition of HDACs. This two-step protocol is also applicable to primary alcohols derived from many other diversity-oriented syntheses since many functional groups can be tolerated under these mild conditions.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported by a grant from the National Institute of General Medical Sciences (NIGMS 38627). We thank Dr. Jianping Cui for numerous helpful discussions, the Chemical Biology Platform of the Broad Institute for enabling smallmolecule screening, and Nicola Tolliday, Jason Burbank, and Stephanie Norton for their help with screening. S.L.S. is an investigator with the Howard Hughes Medical Institute. W. T. was supported as a Research Associate of the Howard Hughes Medical Institute.

References

- (1). Kornberg RD, Lorch YL. Cell. 1999; 98:285. [PubMed: 10458604] Khorasanizadeh S. Cell. 2004; 116:259.
- (2). Jenuwein T, Allis CD. Science. 2001; 293:1074. [PubMed: 11498575] Schreiber SL, Bernstein BE. Cell. 2002; 111:771. [PubMed: 12526804]
- (3). Taunton J, Hassig CA, Schreiber SL. Science. 1996; 272:408. [PubMed: 8602529]

- (4). Yang WM, Yao YL, Sun JM, Davie JR, Seto EJ. *Biol. Chem.* 1997; 272:28001. Grozinger CM, Hassig CA, Schreiber SL. *Proc. Natl. Acad. Sci. U S A.* 1999; 96:4868. [PubMed: 10220385] Kao HY, Downes M, Ordentlich P, Evans RM. *Genes Dev.* 2000; 14:55. [PubMed: 10640276] Zhou XB, Marks PA, Rifkind RA, Richon VM. *Proc. Natl. Acad. Sci. U S A.* 2001; 98:10572. [PubMed: 11535832] Kao HY, Lee CH, Komarov A, Han CC, Evans RM. *J. Biol. Chem.* 2002; 277:187. [PubMed: 11677242] Gao L, Cueto MA, Asselbergs F, Atadja PJ. *Biol. Chem.* 2002; 277:25748.
- (5). Kouzarides T. *Embo J.* 2000; 19:1176. [PubMed: 10716917] Piperno G, Ledizet M, Chang XJ. *J. Cell Biol.* 1987; 104:289. [PubMed: 2879846] Luo JY, Su F, Chen DL, Shiloh A, Gu W. *Nature.* 2000; 408:377. [PubMed: 11099047]
- (6). Wong JC, Hong R, Schreiber SL. *J. Am. Chem. Soc.* 2003; 125:5586. [PubMed: 12733869]
- (7). Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. *Proc. Natl. Acad. Sci. U S A.* 2003; 100:4389. [PubMed: 12677000]
- (8). Miller TA, Witter DJ, Belvedere S. *J. Med. Chem.* 2003; 46:5097. [PubMed: 14613312]
- (9). Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, Civoli F, Breslow R, Rifkind RA, Marks PA. *Proc. Natl. Acad. Sci. U S A.* 1996; 93:5705. [PubMed: 8650156] Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA. *Proc. Natl. Acad. Sci. U S A.* 1998; 95:3003. [PubMed: 9501205] Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP. *Nature.* 1999; 401:188. [PubMed: 10490031] Marks PA, Rifkind RA, Richon VM, Breslow R. *Clin. Cancer Res.* 2001; 7:759. [PubMed: 11309319]
- (10). Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, Warnow T, Mazitschek R. *Nat. Chem. Biol.* 2010; 6:238. [PubMed: 20139990]
- (11). Yoshida M, Matsuyama A, Komatsu Y, Nishino N. *Curr. Med. Chem.* 2003; 10:2351. [PubMed: 14529478] Minucci S, Pelicci PG. *Nat. Rev. Cancer.* 2006; 6:38. [PubMed: 16397526]
- (12). Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D, Osada H, Komatsu Y, Nishino N, Khochbin S, Horinouchi S, Yoshida M. *Embo J.* 2002; 21:6820. [PubMed: 12486003] Suzuki T, Matsuura A, Kouketsu A, Hisakawa S, Nakagawa H, Miyata N. *Bioorg. Med. Chem.* 2005; 13:4332. [PubMed: 15927839] Mai A, Massa S, Pezzi R, Simeoni S, Rotili D, Nebbioso A, Scognamiglio A, Altucci L, Loidl P, Brosch G. *J. Med. Chem.* 2005; 48:3344. [PubMed: 15857140] Wang DF, Helquist P, Wiech NL, Wiest O. *J. Med. Chem.* 2005; 48:6936. [PubMed: 16250652] Paris M, Porcelloni M, Binaschi M, Fattori D. *J. Med. Chem.* 2008; 51:1505. [PubMed: 18247554] Bieliauskas AV, Pflum MKH. *Chem. Soc. Rev.* 2008; 37:1402. [PubMed: 18568166] Chen Y, Lopez-Sanchez M, Savoy DN, Billadeau DD, Dow GS, Kozikowski AP. *J. Med. Chem.* 2008; 51:3437. [PubMed: 18494463] Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD. *J. Med. Chem.* 2008; 51:4370. [PubMed: 18642892] Butler KV, Kalin J, Brochier C, Vistoli G, Langley B, Kozikowski AP. *J. Am. Chem. Soc.* 2010; 132:10842–10846. [PubMed: 20614936]
- (13). For HDAC8-selective inhibitors, see: Hu ED, Dul E, Sung CM, Chen ZX, Kirkpatrick R, Zhang GF, Johanson K, Liu RG, Lago A, Hofmann G, Macarron R, De Los Frailes M, Perez P, Krawiec J, Winkler J, Jaye MJ. *Pharmacol. Exp. Ther.* 2003; 307:720. Krennhubec K, Marshall BL, Hedglin M, Verdin E, Ulrich SM. *Bioorg. Med. Chem. Lett.* 2007; 17:2874. [PubMed: 17346959] Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. *Leukemia.* 2008; 22:1026. [PubMed: 18256683] Galletti P, Quintavalla A, Ventrici C, Giannini G, Cabri W, Penco S, Gallo G, Vincenti S, Giacomini D. *Chemmedchem.* 2009; 4:1991. [PubMed: 19821480] Estiu G, West N, Mazitschek R, Greenberg E, Bradner JE, Wiest O. *Bioorg. Med. Chem.* 2010; 18:4103. [PubMed: 20472442]
- (14). Vannini A, Volpari C, Filocamo G, Casavola EC, Brunetti M, Renzoni D, Chakravarty P, Paolini C, De Francesco R, Gallinari P, Steinkuhler C, Di Marco S. *Proc. Natl. Acad. Sci. U S A.* 2004; 101:15064. [PubMed: 15477595] Somoza JR, Skene RJ, Katz BA, Mol C, Ho JD, Jennings AJ, Luong C, Arvai A, Buggy JJ, Chi E, Tang J, Sang BC, Verner E, Wynands R, Leahy EM, Dougan DR, Snell G, Navre M, Knuth MW, Swanson RV, Mcree DE, Tari LW. *Structure.* 2004; 12:1325. [PubMed: 15242608]
- (15). Sternson SM, Wong JC, Grozinger CM, Schreiber SL. *Org. Lett.* 2001; 3:4239. [PubMed: 11784187]

- (16). Tan DS, Foley MA, Stockwell BR, Shair MD, Schreiber SL. *J. Am. Chem. Soc.* 1999; 121:9073. Sternson SM, Louca JB, Wong JC, Schreiber SL. *J. Am. Chem. Soc.* 2001; 123:1740. [PubMed: 11456775] Hergenrother PJ, Depew KM, Schreiber SL. *J. Am. Chem. Soc.* 2000; 122:7849.
- (17). Ley SV, Bolli MH, Hinzen B, Gervois AG, Hall BJ. *J. Chem. Soc., Perk. Trans. 1.* 1998:2239. Hinzen B, Ley SV. *J. Chem. Soc., Perk. Trans. 1.* 1997:1907.
- (18). Vickerstaffe E, Warrington BH, Ladlow M, Ley SV. *Org. Biomol. Chem.* 2003; 1:2419. [PubMed: 12956055]
- (19). Komatsu Y, Tomizaki K, Tsukamoto M, Kato T, Nishino NK, Sato SG, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H. *Cancer Res.* 2001; 61:4459. [PubMed: 11389076] Furumai R, Komatsu Y, Nishino N, Khochbin S, Yoshida M, Horinouchi S. *Proc. Natl. Acad. Sci. U S A.* 2001; 98:87. [PubMed: 11134513]
- (20). Taunton J, Collins JL, Schreiber SL. *J. Am. Chem. Soc.* 1996; 118:10412.
- (21). Lee D, Sello JK, Schreiber SL. *J. Am. Chem. Soc.* 1999; 121:10648.
- (22). Schwab P, Grubbs RH, Ziller JW. *J. Am. Chem. Soc.* 1996; 118:100.
- (23). See supporting information for details.
- (24). Vegas AJ, Bradner JE, Tang WP, McPherson OM, Greenberg EF, Koehler AN, Schreiber SL. *Angew. Chem., Int. Ed.* 2007; 46:7960.
- (25). Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL. *Chem. Biol.* 2003; 10:383. [PubMed: 12770821]
- (26). Patel V, Mazitschek R, Coleman B, Nguyen C, Urgaonkar S, Cortese J, Barker RH, Greenberg E, Tang WP, Bradner JE, Schreiber SL, Duraisingh MT, Wirth DF, Clardy J. *J. Med. Chem.* 2009; 52:2185. [PubMed: 19317450]
- (27). Strausberg RL, Schreiber SL. *Science.* 2003; 300:294. [PubMed: 12690189] Schreiber SL. *Nat. Chem. Biol.* 2005; 1:64. [PubMed: 16407997]

Figure 1.
TSA, SAHA, trapoxin B, tubacin, and histacin

Figure 2. A two-step protocol for the conversion of diverse primary alcohols to HDAC inhibitors is illustrated.

Figure 3.
Short syntheses of 12-membered macrocyclic aldehydes are illustrated.

Figure 4.
Synthesis of biasing reagents

Figure 5.
Aldehyde building blocks used in the pilot library.

Figure 6.
Structures of selected HDAC8-selective inhibitors

Table 1

Discovery of HDAC8-selective inhibitors using a biochemical assay

Compounds	HDAC2 (IC ₅₀ , μ M)	HDAC3/NCOR2 (IC ₅₀ , μ M)	HDAC8 (IC ₅₀ , μ M)
A12B4	20	18	0.052
A14B3	0.0021	0.0031	0.29
A14B4	6.3	6.2	0.029
A8B4	3.6	15	0.023
A7B4	5	15	0.11
SAHA	0.066	0.034	1.1